Pharmaceutics (Oct 2022)

Optimization of In Vivo Electroporation Conditions and Delivery of DNA Vaccine Encoding SARS-CoV-2 RBD Using the Determined Protocol

  • Denis Nikolaevich Kisakov,
  • Lyubov Alexandrovna Kisakova,
  • Maria Borisovna Borgoyakova,
  • Ekaterina Vladimirovna Starostina,
  • Oleg Svyatoslavovich Taranov,
  • Elena Konstantinovna Ivleva,
  • Oleg Viktorovich Pyankov,
  • Anna Vladimirovna Zaykovskaya,
  • Dmitry Nikolaevich Shcherbakov,
  • Andrey Pavlovich Rudometov,
  • Nadezda Borisovna Rudometova,
  • Natalia Vyacheslavovna Volkova,
  • Vadim Nikolaevich Gureev,
  • Alexander Alexeyevich Ilyichev,
  • Larisa Ivanovna Karpenko

DOI
https://doi.org/10.3390/pharmaceutics14112259
Journal volume & issue
Vol. 14, no. 11
p. 2259

Abstract

Read online

Vaccination against SARS-CoV-2 and other viral infections requires safe, effective, and inexpensive vaccines that can be rapidly developed. DNA vaccines are candidates that meet these criteria, but one of their drawbacks is their relatively weak immunogenicity. Electroporation (EP) is an effective way to enhance the immunogenicity of DNA vaccines, but because of the different configurations of the devices that are used for EP, it is necessary to carefully select the conditions of the procedure, including characteristics such as voltage, current strength, number of pulses, etc. In this study, we determined the optimal parameters for delivery DNA vaccine by electroporation using the BEX CO device. BALB/c mice were used as a model. Plasmid DNA phMGFP was intramuscular (I/M) injected into the quadriceps muscle of the left hind leg of animals using insulin syringes, followed by EP. As a result of the experiments, the following EP parameters were determined: direct and reverse polarity rectangular DC current in three pulses, 12 V voltage for 30 ms and 950 ms intervals, with a current limit of 45 mA. The selected protocol induced a low level of injury and provided a high level of GFP expression. The chosen protocol was used to evaluate the immunogenicity of the DNA vaccine encoding the receptor-binding domain (RBD) of the SARS-CoV-2 protein (pVAXrbd) injected by EP. It was shown that the delivery of pVAXrbd via EP significantly enhanced both specific humoral and cellular immune responses compared to the intramuscular injection of the DNA vaccine.

Keywords